What did @baelarenee actually say?
She lost half a pound in a week on 2.5mg of tirzepatide, injected into her outer thigh this time, and found it painful. She suspects her increased appetite and cravings were tied to her upcoming period rather than the medication failing. She's experimenting with injection sites, moving to below the belly button, and picked up a travel storage container. She's asking her audience a genuine question: do other people on GLP-1 medications notice appetite changes around their cycle?
That's the whole video. No dramatic claims, no miracle framing. Just a person documenting what it's actually like to be on a weight-loss medication week to week. That kind of transparency is more useful than most content in this category.
Does the science back this up?
Yes, and more strongly than most people realize. The menstrual cycle genuinely affects hunger hormones, and this is not bro-science or forum mythology.
Research published by Davidsen et al. (2007, Acta Obstetricia et Gynecologica Scandinavica) found that women consume significantly more calories in the luteal phase, the week or so before menstruation, compared to the follicular phase. The likely driver is progesterone, which rises sharply post-ovulation and appears to counteract some of the satiety signaling that hormones like GLP-1 and leptin normally provide.
A 2020 review by McNeil and Doucet in Physiology and Behavior went further, documenting that energy intake increases by roughly 90 to 500 calories per day during the late luteal phase across multiple studies. Cravings for high-fat, high-carbohydrate foods specifically spike during this window. So when @baelarenee says she had more cravings and appetite right before her period, the biology backs her up completely.
What's less clear is whether tirzepatide's appetite suppression is specifically weaker during the luteal phase. That interaction hasn't been formally studied yet. Her observation is plausible, not proven.
What did they get wrong (or right)?
She got the core intuition right. Attributing increased cravings to her upcoming period rather than blaming the medication or panicking about the scale is actually a sophisticated reading of her own physiology. A lot of people on GLP-1 medications catastrophize small appetite fluctuations. She didn't.
The thigh injection pain is also not unusual. Subcutaneous injections in the lateral thigh can hurt more than abdominal sites for some people because adipose tissue depth varies more in that location, and there's greater muscle proximity. This isn't a flaw in her technique; it's individual anatomy. Rotating sites matters, and she's doing that correctly.
One thing to flag: she mentions injecting "under" her belly button as a new site and frames it as an experiment to see "how the suppression is." Injection site does not meaningfully change how a medication like tirzepatide works systemically. All approved subcutaneous sites, abdomen, thigh, upper arm, produce comparable bioavailability. She may notice differences in local comfort, but attributing suppression changes to site location would be a misread. A half pound of weight difference week to week is well within normal fluctuation for water retention alone, especially premenstrually.
What should you actually know?
A few things worth knowing if you're on a GLP-1 medication and menstruate:
- Expect increased hunger in the week before your period. This is hormonal, not a sign your medication stopped working.
- Tracking your cycle alongside your appetite and weight data gives you a much cleaner picture of actual trends. Apps like Clue or even a basic calendar help separate hormonal noise from medication signal.
- Half a pound of loss in a week while premenstrual is genuinely a reasonable outcome. Premenstrual water retention can mask fat loss entirely, meaning the scale may actually be understating real progress during this phase.
- Injection site rotation is standard practice to prevent lipohypertrophy, hardened fatty tissue that forms when you repeatedly inject the same spot. She's doing this right.
- If you're storing medication for travel, temperature stability matters. Tirzepatide should be kept refrigerated; most room-temperature exposure windows are limited and specified by the manufacturer. A travel container is useful but check your specific product labeling for time and temperature limits.
Bottom line
@baelarenee is asking a question that deserves a real answer, and the real answer is yes, your cycle likely does affect how hungry you feel even on GLP-1 therapy. The mechanism is real, the effect is documented, and the honest thing to say is that researchers haven't yet run controlled trials specifically on GLP-1 efficacy across menstrual phases. Her experience is consistent with what we know. Her interpretation is reasonable. That makes this video more accurate than most in the category.